



Dyve Biosciences to Present at the 2019 BIO Investor Forum

October 17, 2019 – Thousand Oaks, California – Dyve Biosciences, a biotech drug delivery company that has developed a proprietary topical skin penetration technology that broadly enables needle-like drug delivery in a needleless topical, announced today the company will present at the 2019 BIO Investor Forum being held October 22-23, 2019 in San Francisco, CA. Ryan Beal MD, CEO and co-inventor of Dyve's technology, will present and meet with investors and prospective partners at the conference.

Presentation Details:

Topic: Reimagining transdermal drug delivery: subcutaneous injections in a topical cream
Date/Time: Tuesday, October 22nd 9:00 AM
Location: The Westin St. Francis, Elizabethan B
Speaker: Ryan Beal MD

About Dyve Biosciences

Dyve Biosciences is rapidly developing a strong pipeline across a broad range of therapeutic areas based around its proprietary Dyve skin penetration technology. The innovative approach enables therapy to be transported from the surface of the skin into the blood with needle-like speed and pill-like efficiency. Dyve has advanced clinical programs in gout and melasma and a robust pre-clinical and clinical data set across multiple unique molecules. At Dyve, the focus is on robust science, compelling data, and delivering positive patient outcomes. For more information please visit www.dyvebio.com.

Contact

Audra Friis
audra@pascalecommunications.com
917.519.9577

###